This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xing, P. X. Articles by McKenzie, I. F. C. Search for Related Content PubMed PubMed Citation Articles by Xing, P. X. Articles by McKenzie, I. F. C.

Cripto

A Novel Target for Antibody-Based Cancer Immunotherapy

¹ Cancer Immunotherapy Laboratory, Austin Research Institute, Heidelberg, Victoria, Australia, and ² School of Molecular Biosciences, Washington State University, Pullman, Washington

Cripto, a member of the epidermal growth factor-Cripto-FRL-Criptic (EGF-CFC) family, has been described recently as a potential target for immunotherapy (Adkins et al., J Clin Invest 2003;112:575–87). We have produced rat monoclonal antibodies (mAbs) to a Cripto 17-mer peptide, corresponding to the "EGF-like" motif of Cripto. The mAbs react with most cancers of the breast, colon, lung, stomach, and pancreas but do not react or react weakly with normal tissues. The mAbs inhibit cancer cell growth in vitro, and this effect was greater with cytotoxic drugs such as 5-fluorouracil, epirubicin, and cisplatin. The anti-Cripto mAbs prevent tumor development in vivo and inhibit the growth of established tumors of LS174T colon xenografts in Scid mice. The growth inhibitory effects with these mAbs may be greater than those described elsewhere, possibly because of IgM giving more effective cross-linking or binding to a different epitope (EGF-like region versus CFC region). The mechanism of inhibitory effects of the Cripto mAbs includes both cancer cell apoptosis, activation of c-Jun-NH₂-terminal kinase and p38 kinase signaling pathways and blocking of Akt phosphorylation. Thus, Cripto is a unique target, and mAbs to Cripto could be of therapeutic value for human cancers.

This article has been cited by other articles:

				K. Watanabe, S. Hamada, C. Bianco, M. Mancino, T. Nagaoka, M. Gonzales, V. Bailly, L. Strizzi, and D. S. Salomon Requirement of Glycosylphosphatidylinositol Anchor of Cripto-1 for trans Activity as a Nodal Co-receptor J. Biol. Chem., December 7, 2007; 282(49): 35772 - 35786. [Abstract] [Full Text] [PDF]

				K. Watanabe, C. Bianco, L. Strizzi, S. Hamada, M. Mancino, V. Bailly, W. Mo, D. Wen, K. Miatkowski, M. Gonzales, et al. Growth Factor Induction of Cripto-1 Shedding by Glycosylphosphatidylinositol-Phospholipase D and Enhancement of Endothelial Cell Migration J. Biol. Chem., October 26, 2007; 282(43): 31643 - 31655. [Abstract] [Full Text] [PDF]

				P. C. Gray, G. Shani, K. Aung, J. Kelber, and W. Vale Cripto Binds Transforming Growth Factor {beta} (TGF-{beta}) and Inhibits TGF-{beta} Signaling Mol. Cell. Biol., December 15, 2006; 26(24): 9268 - 9278. [Abstract] [Full Text] [PDF]

				C. Bianco, L. Strizzi, M. Mancino, A. Rehman, S. Hamada, K. Watanabe, A. De Luca, B. Jones, G. Balogh, J. Russo, et al. Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5158 - 5164. [Abstract] [Full Text] [PDF]

				Y. Sun, L. Strizzi, A. Raafat, M. Hirota, C. Bianco, L. Feigenbaum, N. Kenney, C. Wechselberger, R. Callahan, and D. S. Salomon Overexpression of Human Cripto-1 in Transgenic Mice Delays Mammary Gland Development and Differentiation and Induces Mammary Tumorigenesis Am. J. Pathol., August 1, 2005; 167(2): 585 - 597. [Abstract] [Full Text] [PDF]